Loading...

Trillium Therapeutics

TSX:TRIL
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
TRIL
TSX
CA$14M
Market Cap
Add to portfolio
  1. Home
    2. ›
  2. CA
    3. ›
  3. Pharmaceuticals & Biotech
Last updated 2019/05/23 23:56
Company description

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The last earnings update was 10 days ago. More info.

Find similar companies

Add to Portfolio Compare Print
  • Trillium Therapeutics has significant price volatility in the past 3 months.
TRIL Share Price and Events
7 Day Returns
-38.2%
TSX:TRIL
2.3%
CA Biotechs
0.6%
CA Market
1 Year Returns
-92.9%
TSX:TRIL
-16.2%
CA Biotechs
-1.2%
CA Market
TRIL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Trillium Therapeutics (TRIL) -38.2% -36.8% -43.3% -92.9% -96.1% -93.3%
CA Biotechs 2.3% 2.5% 0.1% -16.2% -18.1% 12.1%
CA Market 0.6% -1.6% 1.6% -1.2% 12.2% 5.5%
1 Year Return vs Industry and Market
  • TRIL underperformed the Biotechs industry which returned -16.2% over the past year.
  • TRIL underperformed the Market in Canada which returned -1.2% over the past year.
Price Volatility
TRIL
Industry
5yr Volatility vs Market

Value

 Is Trillium Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Trillium Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is CA$0.55.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Trillium Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Trillium Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
TSX:TRIL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in CAD CA$-2.98
TSX:TRIL Share Price ** TSX (2019-05-23) in CAD CA$0.55
North America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 19.79x
Canada Market PE Ratio Median Figure of 542 Publicly-Listed Companies 15.02x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Trillium Therapeutics.

TSX:TRIL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSX:TRIL Share Price ÷ EPS (both in CAD)

= 0.55 ÷ -2.98

 -0.18x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Trillium Therapeutics is loss making, we can't compare its value to the North America Biotechs industry average.
  • Trillium Therapeutics is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Trillium Therapeutics's expected growth come at a high price?
Raw Data
TSX:TRIL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.18x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts		 -5.6%per year
North America Biotechs Industry PEG Ratio Median Figure of 29 Publicly-Listed Biotechs Companies 1.2x
Canada Market PEG Ratio Median Figure of 249 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Trillium Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Trillium Therapeutics's assets?
Raw Data
TSX:TRIL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in CAD CA$0.22
TSX:TRIL Share Price * TSX (2019-05-23) in CAD CA$0.55
Canada Biotechs Industry PB Ratio Median Figure of 36 Publicly-Listed Biotechs Companies 5.55x
Canada Market PB Ratio Median Figure of 2,403 Publicly-Listed Companies 1.44x
TSX:TRIL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSX:TRIL Share Price ÷ Book Value per Share (both in CAD)

= 0.55 ÷ 0.22

 2.48x

* Primary Listing of Trillium Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Trillium Therapeutics is good value based on assets compared to the CA Biotechs industry average.
X
Value checks
We assess Trillium Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
    5. Trillium Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Trillium Therapeutics expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-5.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Trillium Therapeutics expected to grow at an attractive rate?
  • Unable to compare Trillium Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Trillium Therapeutics's earnings growth to the Canada market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Trillium Therapeutics's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
TSX:TRIL Future Growth Rates Data Sources
Data Point Source Value (per year)
TSX:TRIL Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts -5.6%
Canada Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 27.8%
Canada Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 36.7%
Canada Market Earnings Growth Rate Market Cap Weighted Average 14.3%
Canada Market Revenue Growth Rate Market Cap Weighted Average 6%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
TSX:TRIL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
TSX:TRIL Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 0 -55 1
2022-12-31 0 -61 1
2021-12-31 0 -64 2
2020-12-31 0 -52 3
2019-12-31 0 -46 3
TSX:TRIL Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-03-31 -41 -45
2018-12-31 -39 -42
2018-09-30 -37 -45
2018-06-30 -33 -43
2018-03-31 -28 -42
2017-12-31 -27 -45
2017-09-30 -27 -43
2017-06-30 -26 -40
2017-03-31 -26 -36
2016-12-31 -23 -32
2016-09-30 -21 -26
2016-06-30 -20 -19

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Trillium Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Trillium Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
TSX:TRIL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Trillium Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSX:TRIL Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -2.61 -2.61 -2.61 1.00
2022-12-31 -2.47 -2.47 -2.47 1.00
2021-12-31 -2.51 -2.51 -2.51 1.00
2020-12-31 -2.41 -2.24 -2.57 2.00
2019-12-31 -2.22 -2.00 -2.50 4.00
TSX:TRIL Past Financials Data
Date (Data in CAD Millions) EPS *
2019-03-31 -2.98
2018-12-31 -3.06
2018-09-30 -3.39
2018-06-30 -3.50
2018-03-31 -3.80
2017-12-31 -4.61
2017-09-30 -4.93
2017-06-30 -4.96
2017-03-31 -4.60
2016-12-31 -4.06
2016-09-30 -3.33
2016-06-30 -2.54

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Trillium Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Trillium Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Trillium Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Trillium Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Trillium Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Trillium Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Trillium Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Trillium Therapeutics's 1-year growth to the North America Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Trillium Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Trillium Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSX:TRIL Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 -44.60 3.39 44.85
2018-12-31 -42.49 3.58 44.10
2018-09-30 -44.59 4.63 43.64
2018-06-30 -42.88 4.50 41.16
2018-03-31 -42.20 3.94 37.67
2017-12-31 -45.09 3.86 38.29
2017-09-30 -43.45 3.42 36.52
2017-06-30 -40.02 3.48 35.97
2017-03-31 -35.98 3.74 33.16
2016-12-31 -31.73 3.83 29.58
2016-09-30 -25.70 3.73 24.89
2016-06-30 -19.30 3.42 22.13
2016-03-31 -17.27 3.44 20.41
2015-12-31 -14.73 3.01 18.05
2015-09-30 -15.96 2.73 17.52
2015-06-30 -16.98 2.51 14.65
2015-03-31 -15.51 2.62 12.62
2014-12-31 -12.88 2.58 10.17
2014-09-30 -9.95 2.37 7.39
2014-06-30 -8.72 1.98 6.36
2014-03-31 -5.99 1.23 4.74
2013-12-31 -4.29 0.85 3.34
2013-09-30 -3.02 0.76 2.16
2013-06-30 -2.13 0.74 1.42
2013-03-31 -1.07 0.52 0.57
2012-12-31 -1.06 0.47 0.62
2012-09-30 -2.51 0.49 1.18
2012-06-30 -2.74 0.46 1.40

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Trillium Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Trillium Therapeutics has efficiently used its assets last year compared to the North America Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Trillium Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Trillium Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Trillium Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Trillium Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Trillium Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Trillium Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Trillium Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Trillium Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Trillium Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Trillium Therapeutics Company Filings, last reported 1 month ago.

TSX:TRIL Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 42.80 0.00 52.45
2018-12-31 41.60 0.10 45.41
2018-09-30 49.30 0.13 52.10
2018-06-30 61.63 0.16 64.70
2018-03-31 70.66 0.19 73.92
2017-12-31 78.58 0.21 81.79
2017-09-30 64.72 0.24 64.30
2017-06-30 75.41 0.28 72.62
2017-03-31 47.17 0.31 41.35
2016-12-31 58.12 0.34 50.47
2016-09-30 65.74 0.35 55.55
2016-06-30 72.56 0.23 60.07
2016-03-31 79.41 0.25 65.84
2015-12-31 85.80 0.44 86.77
2015-09-30 87.44 0.29 89.08
2015-06-30 88.47 0.25 89.55
2015-03-31 24.21 0.26 25.70
2014-12-31 24.30 0.28 26.17
2014-09-30 28.20 0.30 28.26
2014-06-30 30.42 0.31 30.54
2014-03-31 32.99 0.33 32.39
2013-12-31 33.91 0.34 32.98
2013-09-30 3.78 0.33 2.69
2013-06-30 5.03 0.56 2.82
2013-03-31 3.72 0.00 4.06
2012-12-31 1.38 0.00 1.38
2012-09-30 1.39 0.00 1.57
2012-06-30 1.78 0.00 1.85
  • Trillium Therapeutics has no debt.
  • Trillium Therapeutics has no debt compared to 5 years ago when it was 1%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Trillium Therapeutics has sufficient cash runway for 1.3 years based on current free cash flow.
  • Trillium Therapeutics has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 20.8% each year.
Show me more healthy companies in the Biotechs industry
X
Financial health checks
We assess Trillium Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
    7. Trillium Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Trillium Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Trillium Therapeutics dividends.
If you bought CA$2,000 of Trillium Therapeutics shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Trillium Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Trillium Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
TSX:TRIL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
Canada Market Average Dividend Yield Market Cap Weighted Average of 331 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

TSX:TRIL Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Trillium Therapeutics has not reported any payouts.
  • Unable to verify if Trillium Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Trillium Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Trillium Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Trillium Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Trillium Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
    7. Trillium Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Trillium Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Trillium Therapeutics has no CEO, or we have no data on them.
Management Team Tenure

Average tenure of the Trillium Therapeutics management team in years:

2.4
Average Tenure
  • The tenure for the Trillium Therapeutics management team is about average.
Management Team

Bob Kirkman

TITLE
Executive Chairman
COMPENSATION
CA$177K
AGE
69

Bob Uger

TITLE
Interim President
COMPENSATION
CA$841K
TENURE
0.1 yrs

James Parsons

TITLE
Chief Financial Officer
COMPENSATION
CA$766K
AGE
53
TENURE
7.8 yrs

Penka Petrova

TITLE
Chief Development Officer
COMPENSATION
CA$766K
TENURE
4 yrs

Yaping Shou

TITLE
Chief Medical Officer
COMPENSATION
CA$2M
TENURE
1.1 yrs

Michael Hill

TITLE
Head of Calgary Site

Malik Slassi

TITLE
Senior Vice President of Discovery Research
TENURE
3.3 yrs

Brian Jahns

TITLE
Senior Vice President of Commercial & Business Development
TENURE
1.4 yrs
Board of Directors Tenure

Average tenure and age of the Trillium Therapeutics board of directors in years:

5.2
Average Tenure
69
Average Age
  • The tenure for the Trillium Therapeutics board of directors is about average.
Board of Directors

Bob Uger

TITLE
Interim President
COMPENSATION
CA$841K
TENURE
0.1 yrs

Luke Beshar

TITLE
Director
COMPENSATION
CA$180K
AGE
59
TENURE
5.2 yrs

Bob Kirkman

TITLE
Executive Chairman
COMPENSATION
CA$177K
AGE
69
TENURE
0.1 yrs

Calvin Stiller

TITLE
Director
COMPENSATION
CA$204K
AGE
77
TENURE
7.8 yrs

John Dick

TITLE
Member of Scientific and Clinical Advisory Board
TENURE
7.4 yrs

Michael Moore

TITLE
Director
COMPENSATION
CA$174K
AGE
76
TENURE
6.1 yrs

Tom Reynolds

TITLE
Director
COMPENSATION
CA$179K
AGE
59
TENURE
5.2 yrs

Aaron Schimmer

TITLE
Member of Scientific Advisory Board

Helen Tayton-Martin

TITLE
Director
COMPENSATION
CA$176K
AGE
51
TENURE
1.6 yrs

Henry Friesen

TITLE
Director Emeritus
COMPENSATION
CA$60K
AGE
84
TENURE
0.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
X
Management checks
We assess Trillium Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
    5. Trillium Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

The Trillium Therapeutics (TSE:TRIL) Share Price Is Down 95% So Some Shareholders Are Rather Upset

It seems likely some shareholders believe that Trillium Therapeutics has the funding to invent a new product before too long. … It certainly is a dangerous place to invest, as Trillium Therapeutics investors might realise. … We'd venture that shareholders are concerned about the need for more capital, because the share price has dropped 45% per year, over 5 years.

Simply Wall St - –

Is Trillium Therapeutics Inc's (TSE:TRIL) CEO Pay Fair?

Recognizing whether CEO incentives are aligned with shareholders is a crucial part of investing. … Incentives can be in the form of compensation, which should always be structured in a way that promotes value-creation to shareholders. … CEOs leading companies of similar size and profitability

Simply Wall St - –

Should Your Next Investment In The Healthcare Industry Be In Trillium Therapeutics Inc (TSX:TRIL)?

The growth in development of new drugs for unmet needs, as well as the ongoing and increasing need for biotech drugs as Baby Boomer generation continues to age, are growth drivers for the positive outlook in the biotech industry over the long term. … Healthcare analysts are forecasting for the entire industry, negative growth in the upcoming year , and an overall negative growth rate in the next couple of years. … TRIL lags the pack with its negative growth rate of -95.15% over the past year, which indicates the company will be growing at a slower pace than its biotech peers.

Simply Wall St - –

Company Info

Description

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; and TTI-2341, an epidermal growth factor receptor antagonist, which is in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.

Details
Name: Trillium Therapeutics Inc.
TRIL
Exchange: TSX
Founded: 2004
CA$14,458,857
26,288,831
Website: http://www.trilliumtherapeutics.com
Address: Trillium Therapeutics Inc.
2488 Dunwin Drive,
Mississauga,
Ontario, L5L 1J9,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSX TRIL Common Shares The Toronto Stock Exchange CA CAD 11. Jan 2005
NasdaqCM TRIL Common Shares Nasdaq Capital Market US USD 11. Jan 2005
DB R5WP Common Shares Deutsche Boerse AG DE EUR 11. Jan 2005
LSE 0VLS Common Shares London Stock Exchange GB CAD 11. Jan 2005
Number of employees
Current staff
Staff numbers
59
Trillium Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/23 23:56
End of day share price update: 2019/05/23 00:00
Last estimates confirmation: 2019/05/17
Last earnings filing: 2019/05/13
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Related Companies

© 2019 Simply Wall Street Pty Ltd, Community Design 2845206, US Design Patent #29/544/281, European Design Registration #2845206, Standard & Poor’s Financial Services LLC. All rights reserved.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2019, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2019)